eamdacademy.org-aZwA-1792320838-b789825600 1792320838 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2023 2 2 Claire Martin Julien Robert Sophie Bernard Antoine Girard 2023 10.68159/b789825600 https://eamdacademy.org/pub/journal/3/article/b789825600 Thompson LM. Neurodegeneration: a question of balance. Nature. 2008;45(7188):707-8. 10.1038/452707a Alenazy RH, Abualshamat MM, Alqahs FS, Almutairi AF, Khalid M, Alharbi M, et al. The role of Ocrelizumab in multiple sclerosis treatment. Arch Pharm Pract. 2021;12(3):117-20. 10.51847/y9PZJHI1Gk Di Mauro S, Schon EA. Mitochondrial disorders in the nervous system. Annual Rev Neurosci. 2008;31(1):91-123. 10.1146/annurev.neuro.30.051606.094302 Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegene-rative diseases. Nature. 2006;443(7113):787-95. 10.1038/nature05292 Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecular Med. 2003;4(1-2):21-36. 10.1385/NMM:4:1-2:21 Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurol. 2004;62(11):1984-9. 10.1212/01.WNL.0000129697.01779.0A Ohnishi S, Takano K. Amyloid fibrils from the viewpoint of protein folding. Cell Mol Life Sci. 2004;61(5):511-24. 10.1007/s00018-003-3264-8 Mosaad M, Aljahdali AF. The role of inflammation in early and late phase of Parkinson’s Disease. Pharmacophore. 2021;12(1):51-6. 10.51847/XMX97KPnlC Tsvetkova D, Obreshkova D. Modern approaches and strategies for prevention and therapeutic influence of Alzheimer’s disease. Int J Pharm Res Allied Sci. 2019;8(1):1-16. Tsvetkova D, Obreshkova D, Ivanova St, Hadjieva B. Benefits of acethylcholin-esterase inhibitor Galantamine in treatment of Alzheimer disease and instrumental methods for its analysis in medicinal plants. J Med Pharm Allied Sci. 2016;5(7):99-116. Tsvetkova D, Obreshkova D, Zheleva-Dimitrova D, Saso L. Antioxidant activity of Galanthamine and some of it’s derivatives. Curr Med Chem. 2013;20(36):4595-608. 10.2174/09298673113209990148 Munawar R, Mushtaq N, Ahmad A, Saeed SMG, Usmani S, Akhtar S, et al. Molecular docking, synthesis and biological evaluation of phenacyl derivatives of 9-aminoacridine as anti-Alzheimer’s agent. Pak J Pharm Sci. 2020;33(2):659-68. Munawar R, Mushtaq N, Arif S, Ahmed A, Akhtar S, Ansari S, et al. Synthesis of 9-aminoacridine derivatives as anti-Alzheimer agents. Amer. J Alzheimer’s Dis Other Demen. 2016;31(3):263-9. 10.1177/1533317515603115 Ahmed A, Akhtar S, Mushtaq N, Haider S, Munawar R, Siddique HA, et al. 1,3-di-4-piperidylpropane derivatives as potential acetylcholinesterase antagonists: molecular docking, synthesis, and biological evaluation. Pak J Pharm Sci. 2021;34(3):855-60. Anand A, Thakur K, Gupta PK. ALS and oxidative stress: the neurovascular scenario. Oxidat Med Cell Longev. 2013(1):635831. Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Ienco EC, Alessi R, et al. Strategies for clinical approach to neurodegeneration in Amyotrophic Lateral Sclerosis. Arch Ital Biol. 2011;149(1):151-67. 10.4449/aib.v149i1.1267 Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic Lateral Sclerosis. Lancet. 2011;377(9769):942-55. 10.1016/S0140-6736(10)61156-7 Cunha-Oliveira T, Montezinho L, Mendes C, Firuzi O, Saso L, Oliveira PJ, et al. Oxidative stress in Amyotrophic Lateral Sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. (Special Issue: Pharmaceutical and Pharmacological Aspects of Modulation of Oxidative Stress). 2020;2020(1):5021694. Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of Amyotrophic Lateral Sclerosis: a systematic review of the published literature. Neuroepidemiol. 2013;41(2):118-30. 10.1159/000351153 Miller RG, Mitchell JD, Moore DH. Riluzole for Amyotrophic Lateral Sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3(1):CD001447. 10.1002/14651858.CD001447.pub3 De Jesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron. 2011;72(2):245-56. 10.1016/j.neuron.2011.09.011 Ginting S, Afniwati Y. The effect of brain GYM on the dementia and depression reduction of the elderly. J Adv Pharm Educ Res. 2021;11(2):40-4. 10.51847/Cj6189cIbl Chiò A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of Amyotrophic Lateral Sclerosis: a population based study. J Neurol Neurosurg Psychiatr. 2011;82(7):740-6. 10.1136/jnnp.2010.235952 Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O’Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11(4):420-2. 10.1038/nn2073 Ahmadi M, Liu JX, Brännström T, Andersen PM, Stål P, Pedrosa-Domellöf F. Human extraocular muscles in ALS. Invest Ophthalmol Vis Sci. 2010;51(7):3494-501. 10.1167/iovs.09-5030 D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic Amyotrophic Lateral Sclerosis. Free Radic Biol Med. 2013;65:509-27. 10.1016/j.freeradbiomed.2013.06.029 Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Human Molecul Genet. 2010;19(R1):46-64. Kuźma-Kozakiewicz M. Pathogenesis of Amyotrophic Lateral Sclerosis. Biomed Rev. 2011;31(22):7-14. 10.14748/BMR.V22.31 Battistini S, Ricci C, Lotti EM, Benigni M, Gagliardi S, Zucco R, et al. Severe familial ALS with a novel exon 4 mutation (L106F) in the SOD1 gene. J Neurol Sci. 2010;293(1-2):112-5. 10.1016/j.jns.2010.03.009 Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211-5. 10.1038/nature10353 Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile Amyotrophic Lateral Sclerosis. Annals Neurol. 2011;70(6):913-9. 10.1002/ana.22534 Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al. Mutations in the profilin 1 gene cause familial Amyotrophic Lateral Sclerosis. Nature. 2012;488(7412):499-503. 10.1038/nature11280 Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause Amyotrophic Lateral Sclerosis type 19. Am J Hum Genet. 2013;93(5):900-5. 10.1016/j.ajhg.2013.09.008 Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al. Mutations in the prion-like domains of hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467-73. 10.1038/nature11922 Bogaert E, van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, et al. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging. 2010;31(12):2185-91. 10.1016/j.neurobiolaging.2008.12.007 Skene JHP, Cleveland DW. Hypoxia and Lou Gehrig. Nat Genet. 2001;28(2):107-8. 10.1038/88805 Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al. Mutations in CHMP2B in lower motor neuron predominant Amyotrophic Lateral Sclerosis (ALS). PLoS One. 2010;5(3):1-6 (e9872). 10.1371/journal.pone.0009872 Nishimura AL, Mitne-Neto M, Silva HCA, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Amer J Human Genet. 2004;75(5):822-31. 10.1086/425287 Puls I, Jonnakuty C, LaMonte HB, Holzbaur ELF, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33(4):455-6. 10.1038/ng1123 Fernandez-Santiago R, Hoenig S, Lichtner P, Sperfeld AD, Sharma M, Berg D, et al. Identification of novel angiogenin (ANG) gene missense variants in german patients with Amyotrophic Lateral Sclerosis. J Neurol. 2009;256(8):1337-42. Cronin S, Greenway MJ, Ennis S, Kieran D, Green A, Prehn JHM, et al. Elevated serum angiogenin levels in ALS. Neurol. 2006;67(10):1833-6. 10.1212/01.wnl.0000244466.46020.47 Bonnefont-Rousselot D, Lacomblez L, Jaudon M, Lepage S, Salachas F, Bensimon G, et al. Blood oxidative stress in amyotrophic lateral sclerosis. J Neurol Sci. 2000;178(1):57-62. 10.1016/s0022-510x(00)00365-8 Barbeito LH, Pehar M, Cassina P, Vargas MR, Peluffo H, Viera L, et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Rev. 2004;47(1-3):263-74. 10.1016/j.brainresrev.2004.05.003 Moylan JS, Reid MB. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve. 2007;35(4):411-29. 10.1002/mus.20743 Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M, Firoozabadi A. Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem. 2012;19(23):4000-5. 10.2174/092986712802002572 Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52(4):601-23. 10.1373/clinchem.2005.061408 Wiktorowska-Owczarek A, Nowak JZ. Pathogenesis and prophylaxis of AMD: focus on oxidative stress and antioxidants. Postepy Hig Med Dosw. 2010;64:333-43. Firuzi O, Spadaro A, Spadaro C, Riccieri V, Petrucci R, Marrosu G, et al. Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients. J Clin Lab Anal. 2008;22(3):210-5. 10.1002/jcla.20243 Losada-Barreiro S, Bravo-Díaz C. Free radicals and polyphenols: the redox chemistry of neurodegenerative diseases. Eur J Med Chem. 2016;133(16):379-402. 10.1016/j.ejmech.2017.03.061 Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des. 2010;6(25):2766-78. 10.2174/138161210793176572 Axelsen PH, Komatsu H, Murray IVJ. Oxidative stress and cell membranes in the pathogenesis of Alzheimer’s disease. Physiol. 2011;26(1):54-69. 10.1152/physiol.00024.2010 Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9(3):177-83. 10.1080/17482960801933942 Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environment Sci Health C, Environ Carcinog Ecotoxicol Rev. 2009;27(2):120-39. 10.1080/10590500902885684 Pratt AJ, Getzoff ED, Perry JJP. Amyotrophic Lateral Sclerosis: update and new developments. Degener Neurol Neuromuscul Dis. 2012(2):1-14. 10.2147/DNND.S19803 Jenkins TM, Hollinger H, McDermott CJ. The evidence for symptomatic treatments in Amyotrophic Lateral Sclerosis. Curr Opin Neurol. 2014;27(5):524-31. 10.1097/WCO.0000000000000135 Fang T, Al-Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which Riluzole treatment prolongs survival in patients with Amyotrophic Lateral Sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416-22. 10.1016/S1474-4422(18)30054-1 Georgoulopoulou E, Fini N, Vinceti M, Monelli M, Vacondio P, Bianconi G, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy. Amyotroph Lateal Scler Frontotemporal Degener. 2013;14(5-6):338-45. 10.3109/21678421.2013.763281 Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients. Degener Neurol Neuromuscul Dis. 2017;7:61-70. 10.2147/DNND.S135748 Lee CTC, Chiu YW, Wang KC, Hwang CS, Lin KH, Lee IT, et al. Riluzole and prognostic factors in Amyotrophic Lateral Sclerosis long-term and short-term survival: a population-based study of 1149 Cases in Taiwan. J Epidemiol. 2013;23(1):35-40. 10.2188/jea.je20120119 Calvo AC, Manzano R, Mendonca DM, Munoz MJ, Zaragoza P, Osta R. Amyotrophic Lateral Sclerosis: a focus on disease progression. Biomed Res Int. 2014(1):925101. Chen L, Liu X, Tang L, Zhang N, Fan D. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China. Front Aging Neurosci. 2016;8:246. 10.3389/fnagi.2016.00246 Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for Amyotrophic Lateral Sclerosis. Clin Epidemiol. 2015;7(1):181-93. eCollection 2015 10.2147/CLEP.S37505. Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating Amyotrophic Lateral Sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17(2):4-31. 10.1111/j.1755-5949.2009.00116.x Pourshams M, Shhrooie S. Investigating the prevalence and risk factors of depression disorders in the elderly: 2019. Entomol Appl Sci Lett. 2021;8(4):20-6. 10.51847/S0qCQp8qHI Dyer AM, Smith A. Riluzole 5 mg/ml oral suspension: for optimized drug delivery in Amyotrophic Lateral Sclerosis. Drug Des Devel Ther. 2016;11(1):59-64. 10.2147/DDDT.S123776 Keating GM. Riluzole oral suspension in Amyotrophic Lateral Sclerosis: a guide to its use. Drugs Ther Perspect. 2016;32(7):282-6. 10.1007/S40267-016-0312-7 Orrell RW. Motor neuron disease: systematic reviews of treatment for ALS and SMA. Br Med Bull. 2010;93(1):145-59. Orrell RW, Lane RJM, Ross M. A systematic review of antioxidant treatment for Amyotrophic Lateral Sclerosis/motor neuron disease. Amyotroph Later Scleros. 2008;9(4):195-211. 10.1080/17482960801900032 Liua J, Wang LN. The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis. Drug Deliv. 2018;25(1):43-8. 10.1080/10717544.2017.1413446 Viswanad V, Anand P, Shammika P. Advancement of Riluzole in neurodegeneative disease. Int J Pharm Clin Res. 2017;9(3):214-7. 10.25258/ijpcr.v9i3.8321 Braz CA, Borges V, Ferraz HB. Effect of Riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol. 2004;27(1):25-9. 10.1097/00002826-200401000-00008 Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(1):156-71. Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imag. 2009;36(7):1113-20. 10.1007/s00259-009-1103-3 Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. Riluzole in cerebellar ataxia:a randomized, double-blind, placebo-controlled pilot trial. Neurol. 2010;74(10):839-45. 10.1212/WNL.0b013e3181d31e23 Romano S, Coarelli G, Marcotulli C, Leonardi L, Piccolo F, Spadaro M, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(10):985-91. 10.1016/S1474-4422(15)00201-X Schmidt J, Schmidt T, Golla M, Lehmann L, Weber JJ, Hübener-Schmid J, et al. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. J Neuroichem. 2016;138(1):150-62. Riess O, Rub U, Pastore A, Bauer P, Schols L. SCA3: neurological features, pathogenesis and animal models. Cerebelum. 2008;7(2):125-37. 10.1007/s12311-008-0013-4 Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480(7378):543-6. 10.1038/nature10671 Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005;6(10):743-55. 10.1038/nrg1691 Zarate CA, Manji HK. Riluzole in psychiatry: a systematic review of the literature. Expert Opin. Drug Metab Toxicol. 2008;4(9):1223-34. 10.1517/17425255.4.9.1223 Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SMR, Yekehtaz H, et al. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacol (Berl.). 2014;231(3):533-42. 10.1007/s00213-013-3261-z Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Pediatric Drugs. 2013;15(6):505-14. 10.1007/s40272-013-0036-2 Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008;22(9):761-86. 10.2165/00023210-200822090-00004 Gourley SL, Espitia JW, Sanacora G, Taylor JR. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacol. 2012;219(3):805-14. 10.1007/s00213-011-2403-4 Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci. 2005;233(1-2):113-5. 10.1016/j.jns.2005.03.011 Fehlings MG, Nakashima H, Nagoshi N, Chow DSL, Grossman RG, Kopjar B. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. Spinal Cord. 2016;54(1):8-15. 10.1038/sc.2015.95 Rajasekaran S, Aiyer SN, Shetty AP, Kanna RM, Maheswaran A, Shetty JY. Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial. Eur Spine J. 2016;25(6):1830-5. 10.1007/s00586-015-4323-1 Chow DSL, Teng Y, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, et al. Pharmacology of Riluzole in acute spinal cord injury. J Neurosurg Spine. 2012;17(Suppl. 1):129-40. 10.3171/2012.5.AOSPINE12112 Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna). 2005;112(5):649-60. 10.1007/s00702-004-0220-1 Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in ALS. Neurol. 2004;63(9):1656-61. 10.1212/01.wnl.0000142992.81995.f0 Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in Amyotrophic Lateral Sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;(6):CD005226. 10.1002/14651858.CD005226.pub2